Vascular Allografts Market Report 2025

The vascular allografts market size has grown strongly in recent years. It will grow from $1.71 billion in 2024 to $1.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to the increasing prevalence of cardiovascular diseases, rising demand for vascular grafts in bypass surgeries, a growing number of vascular trauma cases requiring grafts, increased awareness of the benefits of organ transplantation, and wider adoption of vascular allografts in reconstructive surgeries.

The vascular allografts market size is expected to see strong growth in the next few years. It will grow to $2.41 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth during the forecast period can be attributed to rising healthcare expenditures in developing regions, increasing regulatory approvals for vascular allograft products, growing awareness of minimally invasive vascular repair techniques, expanding use of vascular allografts in diabetic limb salvage, and rising demand for customized, patient-specific vascular grafts. Key trends expected in the forecast period include advancements in tissue preservation technologies, development of advanced biomaterials for vascular grafts, innovations in cryopreservation methods, integration of regenerative medicine approaches, progress in 3D bioprinting for vascular grafts, and the use of advanced imaging for graft compatibility.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the vascular allografts market in the coming years. Cardiovascular diseases comprise a range of disorders affecting the heart and blood vessels, including coronary heart disease, heart failure, stroke, and hypertension. This increase is largely attributed to poor dietary habits, as excessive intake of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels. Vascular allografts improve treatment options for cardiovascular diseases by providing ready-to-use donor blood vessels, making them particularly suitable for patients with damaged or diseased vessels. They enhance surgical outcomes by restoring proper blood flow, minimizing complications, and supporting long-term cardiovascular health. For example, in January 2024, the American Heart Association, a US-based nonprofit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2022, up 4% from 224.4 per 100,000 in 2021. Therefore, the growing prevalence of cardiovascular diseases is driving the expansion of the vascular allografts market.

Key players in the vascular allografts market are focusing on developing advanced products, such as bioengineered graft materials, to improve graft durability, biocompatibility, and integration with host tissue. Bioengineered graft materials are specially designed vascular grafts created using advanced biological and engineering techniques. For instance, in February 2025, Humacyte Inc., a US-based biotechnology company, launched Symvess, a bioengineered vascular graft designed for adults requiring urgent revascularization due to extremity arterial injuries when autologous vein grafts are not an option. Symvess is engineered to remodel into the patient’s own tissue over time, reducing the risk of rejection and improving long-term outcomes. This graft also minimizes the need for immunosuppressive drugs, offering significant advantages in trauma and emergency surgical settings.

In May 2025, MTF Biologics, a US-based nonprofit organization, partnered with Kolosis BIO LLC to introduce innovative allograft products. This collaboration aims to expand access to advanced allograft solutions, improve surgical outcomes, and provide surgeons with high-quality, ready-to-use grafts for complex vascular and orthopedic procedures. Kolosis BIO LLC, based in the US, specializes in the development and commercialization of vascular allograft products.

Major players in the vascular allografts market are Medtronic plc, Boston Scientific Corporation, Terumo Corporation, W. L. Gore & Associates Inc., Dentsply Sirona Inc., Integra LifeSciences Holdings Corporation, MicroPort Scientific Corporation, Bioventus Inc., KLS Martin Group, MTF Biologics, MTF Biologics, ZimVie Inc., B. Braun Melsungen AG, Artivion Inc., MiMedx Group Inc., RTI Surgical Inc, LeMaitre Vascular Inc., LifeNet Health Inc., Xtant Medical Holdings Inc., Biotech Dental.

North America was the largest region in the vascular allografts market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vascular allografts market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular allografts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Vascular allografts are blood vessels harvested from a human donor and transplanted into another patient to replace or bypass damaged or diseased vessels. They are used to restore blood flow in cases where a patient’s own vessels are unsuitable for grafting, such as during bypass surgeries or vascular reconstruction.

The primary types of vascular allografts include cortical allografts, cancellous allografts, and corticocancellous allografts. Cortical allografts are derived from the dense outer layer of donor bone and are used to provide structural support and promote bone healing in orthopedic and dental procedures. These allografts utilize materials such as biologic, synthetic, composite, and polymer-based materials, and find applications in cardiovascular surgery, peripheral vascular surgery, transplant surgery, and repair of congenital defects. Distribution channels include direct sales, online platforms, distributors, and medical supply stores, catering to end-users such as hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research and academic institutions.

The vascular allografts market research report is one of a series of new reports that provides vascular allografts market statistics, including vascular allografts industry global market size, regional shares, competitors with a vascular allografts market share, detailed vascular allografts market segments, market trends and opportunities, and any further data you may need to thrive in the vascular allografts industry. These vascular allografts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vascular allografts market consists of sales of arterial allografts, venous allografts, cryopreserved vascular grafts, fresh vascular grafts, and decellularized vascular allografts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.